TNDM Quote, Financials, Valuation and Earnings

Beta Bionics has a net margin of 0.27% compared to Tandem Diabetes Care's net margin of --. Tandem Diabetes Care's return on equity of -37.18% beat Beta Bionics's return on equity of --.

Tandem Diabetes Care has a consensus price target of $38.24, signalling upside risk potential of 111.73%. On the other hand Beta Bionics has an analysts' consensus of $25.71 which suggests that it could grow by 134.62%. Given that Beta Bionics has higher upside potential than Tandem Diabetes Care, analysts believe Beta Bionics is more attractive than Tandem Diabetes Care.

Tandem Diabetes Care has a beta of 1.525, which suggesting that the stock is 52.461% more volatile than S&P 500. In comparison Beta Bionics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beta Bionics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Beta Bionics pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $282.6M, which are larger than Beta Bionics quarterly revenues of --. Tandem Diabetes Care's net income of $755K is higher than Beta Bionics's net income of --. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Beta Bionics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.26x versus -- for Beta Bionics. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 0.27% compared to Tandem Diabetes Care's net margin of 14.45%. Tandem Diabetes Care's return on equity of -37.18% beat Boston Scientific's return on equity of 8.96%.

Tandem Diabetes Care has a consensus price target of $38.24, signalling upside risk potential of 111.73%. On the other hand Boston Scientific has an analysts' consensus of $117.06 which suggests that it could grow by 14.88%. Given that Tandem Diabetes Care has higher upside potential than Boston Scientific, analysts believe Tandem Diabetes Care is more attractive than Boston Scientific.

Tandem Diabetes Care has a beta of 1.525, which suggesting that the stock is 52.461% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $282.6M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Tandem Diabetes Care's net income of $755K is lower than Boston Scientific's net income of $674M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 74.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.26x versus 8.64x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 0.27% compared to Tandem Diabetes Care's net margin of 30.99%. Tandem Diabetes Care's return on equity of -37.18% beat Intuitive Surgical's return on equity of 15.82%.

Tandem Diabetes Care has a consensus price target of $38.24, signalling upside risk potential of 111.73%. On the other hand Intuitive Surgical has an analysts' consensus of $576.03 which suggests that it could grow by 11.94%. Given that Tandem Diabetes Care has higher upside potential than Intuitive Surgical, analysts believe Tandem Diabetes Care is more attractive than Intuitive Surgical.

Tandem Diabetes Care has a beta of 1.525, which suggesting that the stock is 52.461% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $282.6M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Tandem Diabetes Care's net income of $755K is lower than Intuitive Surgical's net income of $698.4M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 75.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.26x versus 21.44x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 0.27% compared to Tandem Diabetes Care's net margin of 16.85%. Tandem Diabetes Care's return on equity of -37.18% beat Insulet's return on equity of 43.11%.

Tandem Diabetes Care has a consensus price target of $38.24, signalling upside risk potential of 111.73%. On the other hand Insulet has an analysts' consensus of $312.27 which suggests that it could grow by 19.78%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Tandem Diabetes Care has a beta of 1.525, which suggesting that the stock is 52.461% more volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $282.6M, which are smaller than Insulet quarterly revenues of $597.5M. Tandem Diabetes Care's net income of $755K is lower than Insulet's net income of $100.7M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Insulet's PE ratio is 45.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.26x versus 9.30x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.